此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

分流器支架国际注册 (IRF) (IRF)

2026年9月17日 更新者:Montefiore Medical Center

分流器治疗颅内动脉瘤的结果 - 国际分流器支架注册中心 (IRF)

This multicenter retrospective cohort study aims to evaluate and compare the technical performance, safety, and clinical outcomes of intracranial aneurysms treated with flow diverter stents and endosaccular flow disruptors.

研究概览

地位

招聘中

详细说明

Flow diverters and endosaccular flow disruptors used for the treatment of intracranial aneurysms exhibit distinct procedural and clinical outcomes, with potential differences in device-specific parameters such as procedure time, radiation exposure, adjunct device requirements, and long-term angiographic success. Since the completion of the Pipeline Embolization Device (PED) for the Intracranial Treatment of Aneurysms trial, the field of flow diversion has undergone continuous evolution with the development and approval of several devices. While these devices share a similar mechanism for aneurysm occlusion, their design and delivery systems can vary significantly. Various studies have demonstrated a promising safety and efficacy profile; however, the available data for a direct comparison of the technical and clinical outcomes between these devices remains limited.

The following collaborator is also involved in the research:

Name: Muhammed Amir Essibayi Email: m.amir.essibayi@gmail.com

研究类型

观察性的

注册 (估计的)

5000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M5B 1W8
      • Toronto、Ontario、加拿大、M5T 2S8
        • 招聘中
        • Toronto Western Hospital
        • 接触:
        • 首席研究员:
          • Pascal Mosimann, MD, PD
    • Florida
      • Coral Gables、Florida、美国、33146
        • 招聘中
        • University of Miami
        • 接触:
        • 首席研究员:
          • Robert M Starke, MD, MS
      • Jacksonville、Florida、美国、32224
        • 完全的
        • Mayo Clinic Florida
      • Sarasota、Florida、美国、34239
        • 完全的
        • Sarasota Memorial Research Institute
    • Massachusetts
      • Burlington、Massachusetts、美国、01805
        • 招聘中
        • Lahey Hospital and Medical Center
        • 接触:
        • 首席研究员:
          • Timo Krings, MD, PhD, MSc
    • Michigan
      • Traverse City、Michigan、美国、49684
        • 招聘中
        • Munson Medical Center
        • 接触:
    • Minnesota
      • Minneapolis、Minnesota、美国、55404
    • New Jersey
      • New Brunswick、New Jersey、美国、08901
        • 招聘中
        • Robert Wood Johnson University
        • 首席研究员:
          • Gaurav Gupta, MD
        • 接触:
    • New York
      • Buffalo、New York、美国、14068
        • 完全的
        • University at Buffalo
      • The Bronx、New York、美国、10467
        • 招聘中
        • Montefiore Medical Center Department of Neurosurgery
        • 首席研究员:
          • David Altschul, MD
        • 接触:
        • 接触:
    • Pennsylvania
      • Danville、Pennsylvania、美国、17822
        • 完全的
        • Geisinger Health
    • Texas
      • Kingwood、Texas、美国、77339
        • 完全的
        • HCA Houston Healthcare Kingwood

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients with intracranial aneurysms who underwent endovascular treatment with flow diverter stents or endosaccular flow disruptors

描述

Inclusion Criteria:

  • Consecutive adult patients (18 years of age or older)

  • Underwent endovascular treatment with one of the following devices:

    a. Endoluminal Flow Diverter Stents: i. Pipeline Flex (Covidien, California, USA) ii. Pipeline Flex with Shield Technology (Covidien) iii. Surpass Streamline (Stryker Neurovascular, California, USA) iv. Surpass Evolve (Stryker) v. Silk flow diverter (Balt Extrusion, Montmorency, France) vi. Flow-Redirection Intraluminal Device (FRED; MicroVention) vii. Flow-Redirection Intraluminal Device X (FRED X; MicroVention) viii. p64 Flow Modulation Device (phenox GmbH) ix. Endovascular clip system (eCLIPs) (eCLIPsTM, eVasc Neurovascular, Vancouver, BC, Canada)

    b. Intrasaccular Flow Disruptors: i. Woven EndoBridge (WEB; MicroVention) ii. Luna/Artisse System (Medtronic) iii. Medina Embolic Device (Medtronic) iv. Contour Neurovascular System (Cerus Endovascular) v. Neqstent Coil Assisted Flow Diverter (Cerus Endovascular) vi. pCONus and pCANvas (phenox GmbH) vii. Nexus Aneurysm Embolization System (EndoStream Medical) viii. CITADEL™ Embolization Device (Balt, USA)

  • Complete medical records and follow-up data available

Exclusion Criteria:

  • Incomplete procedural or follow-up records
  • Non-flow-diverter or non-flow-disruptor treatments (e.g., coiling-only cases)
  • Aneurysms treated with investigational devices not listed within Inclusion Criteria

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:RETROSPECTIVE

队列和干预

团体/队列
Endoluminal Flow Diverter Stent

Adults with intracranial aneurysms treated with an endoluminal flow diverter stent as part of routine care.

Intrasaccular Flow Disruptor

Adults with intracranial aneurysms treated with an intrasaccular flow disruptor as part of routine care.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Technical Success
大体时间:Periprocedurally, up to 24 hours

Technical Success will be determined by successful deployment of the flow diverter stent or endosaccular flow disruptors. A dichotomous determination (i.e., Yes/No) will be made and summarized for this study.

Periprocedurally, up to 24 hours
Procedural Complications following placement
大体时间:From the time of the procedure up to 1 month post treatment

Procedural complications will be identified as the number of instances of the following adverse clinical events: In-stent Thrombosis/Stenosis; Ischemic complications (Transient Ischemic Attack/Stroke), Intracerebral hemorrhage, Aneurysm rupture, and Vessel occlusion due to flow diverter stent or endosaccular flow disruptor placement.

From the time of the procedure up to 1 month post treatment
Clinical Outcomes at Discharge
大体时间:Upon study discharge, up to 4 weeks

Clinical outcomes at discharge will be assessed using the modified Rankin Scale (mRS) for neurologic disability. The mRS is a 6-point disability scale with possible scores ranging from 0-5. mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Higher scores are generally associated with less favorable outcomes. For this study patients with an mRS score of 0-2 will be determined to have had a "favorable" outcome to the procedure and patients with an mRS score of 3-5 will have been determined to have had an "unfavorable" outcome.

Upon study discharge, up to 4 weeks
Clinical Outcomes at last available Follow-up
大体时间:Up to 24 months post procedure

Clinical outcomes at last available follow-up will be assessed using a variant of the modified Rankin Scale (mRS) for neurologic disability. The classic mRS is a 6-point disability scale with possible scores ranging from 0-5. mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Higher scores are generally associated with less favorable outcomes. For this study patients with an mRS score of 0-2 will be determined to have had a "favorable" outcome to the procedure and patients with an mRS score of 3-5 will have been determined to have had an "unfavorable" outcome. Scoring will also include a 6 to identify patients who have expired.

Up to 24 months post procedure
Immediate Angiographic Outcomes at Discharge - O'Kelly-Marotta (OKM) grading scale
大体时间:Upon study discharge, up to 4 weeks

Immediate Angiographic Outcomes at Discharge will be evaluated using the OKM grading scale. The OKM scale will be used to assess the degree of angiographic filling and in the setting of intracranial aneurysms which were treated by endovascular flow diversion. It is used to predict aneurysm closure over time. Patient outcomes will be stratified based on the following scale scores: Grade A: Total filling (>95% of aneurysm remained); Grade B: Subtotal filling (5-95% of aneurysm remained); Grade C: Entry remnant (<5% aneurysm remained); and Grade D: No filling (0% aneurysm remained). As such, the less aneurysm remnant the more favorable the angiographic outcome. The number/percentage of cases of each OKM Grade will be summarized.

Upon study discharge, up to 4 weeks
Immediate Angiographic Outcomes at Discharge - Modified Raymond-Roy Classification (mRRC)
大体时间:Upon study discharge, up to 4 weeks

Immediate Angiographic Outcomes at Discharge will also be evaluated using mRRC categorization. mRRC categorization will be used to assess the degree of occlusion achieved when treating an intracranial aneurysm. It categorizes the level of residual contrast filling within an aneurysm after coiling. For purposes of this analysis, Class I will signify complete occlusion; Class II will signify Residual neck occlusion; Class IIIa will signify Residual aneurysm with contrast stasis; and Class IIIb will signify Residual aneurysm without contrast stasis. As such, it is an indicator of how effectively the aneurysm has been sealed off during treatment. The number/percentage of cases of each mRRC category will be summarized.

Upon study discharge, up to 4 weeks
Immediate Angiographic Outcomes at Discharge - WEB Occlusion Scale (WOS)
大体时间:Upon study discharge, up to 4 weeks

Immediate Angiographic Outcomes at Discharge will be evaluated using the WOS grading scale. The WOS is a standardized angiographic assessment scale for reporting aneurysm occlusion achieved with endosaccular flow disruptors and can be employed to assess the adequacy of treatment. For purposes of this analysis, WOS Grade A will signify complete occlusion; WOS Grade B will signify Residual neck occlusion; and WOS Grade C will signify Residual aneurysm filling. The number/percentage of cases of each WOS grade category will be summarized.

Upon study discharge, up to 4 weeks
Angiographic Outcomes at last available Follow-up - O'Kelly-Marotta (OKM) grading scale
大体时间:Up to 24 months post procedure

Immediate Angiographic Outcomes at Discharge will be evaluated using the OKM grading scale. The OKM scale will be used to assess the degree of angiographic filling and in the setting of intracranial aneurysms which were treated by endovascular flow diversion. It is used to predict aneurysm closure over time. Patient outcomes will be stratified based on the following scale scores: Grade A: Total filling (>95% of aneurysm remained); Grade B: Subtotal filling (5-95% of aneurysm remained); Grade C: Entry remnant (<5% aneurysm remained); and Grade D: No filling (0% aneurysm remained). As such, the less aneurysm remnant the more favorable the angiographic outcome. The number/percentage of cases of each OKM Grade will be summarized.

Up to 24 months post procedure
Angiographic Outcomes at last available Follow-up - Modified Raymond-Roy Classification (mRRC)
大体时间:Up to 24 months post procedure

Immediate Angiographic Outcomes at Discharge will also be evaluated using mRRC categorization. mRRC categorization will be used to assess the degree of occlusion achieved when treating an intracranial aneurysm. It categorizes the level of residual contrast filling within an aneurysm after coiling. For purposes of this analysis, Class I will signify complete occlusion; Class II will signify Residual neck occlusion; Class IIIa will signify Residual aneurysm with contrast stasis; and Class IIIb will signify Residual aneurysm without contrast stasis. As such, it is an indicator of how effectively the aneurysm has been sealed off during treatment. The number/percentage of cases of each mRRC category will be summarized.

Up to 24 months post procedure
Angiographic Outcomes at last available Follow-up - WEB Occlusion Scale (WOS)
大体时间:Up to 24 months post procedure

Immediate Angiographic Outcomes at Discharge will be evaluated using the WOS grading scale. The WOS is a standardized angiographic assessment scale for reporting aneurysm occlusion achieved with endosaccular flow disruptors and can be employed to assess the adequacy of treatment. For purposes of this analysis, WOS Grade A will signify complete occlusion; WOS Grade B will signify Residual neck occlusion; and WOS Grade C will signify Residual aneurysm filling. The number/percentage of cases of each WOS grade category will be summarized.

Up to 24 months post procedure

次要结果测量

结果测量
措施说明
大体时间
Radiation Exposure
大体时间:Periprocedurally, up to 4 hours

Radiation exposure over the course of the procedure will be extracted and summarized. Radiation exposure will be evaluated based on relevant imaging system metrics used to calculate the total radiation dose delivered to the patient based on the fluoroscopy time and the area of the X-ray field exposed during the procedure. Flow diverter stents and endosaccular flow disruptors typically result in significantly lower radiation exposure compared to other endovascular techniques for treating brain aneurysms due to a reduction in fluoroscopy time and overall reduced radiation dose due to the streamlined nature of the procedures.

Periprocedurally, up to 4 hours
Procedure Duration
大体时间:Periprocedurally, up to 4 hours

The duration of procedure placement will be extracted and summarized. The duration of the procedure is influenced by the complexity of the aneurysm, the patient's anatomy, and the experience of the interventional radiologist and care team. Shorter procedure duration times are associated with more favorable outcomes.

Periprocedurally, up to 4 hours
Use of Adjunct Devices
大体时间:Periprocedurally, up to 4 hours

The use of adjunctive devices such as coils, stents or balloons to further enhance aneurysm occlusion of the flow diverter stent or to facilitate positioning and deployment of the endosaccular flow disruptor within the aneurysm sac during the procedure will be extracted and summarized. The number of adjunct devices will be extracted and summarized.

Periprocedurally, up to 4 hours
Recurrence of Aneurysm
大体时间:6 to 24 months post procedure

The percentage of patients who experienced aneurysm recurrence will be extracted and summarized based on a binary (Yes/No) determination following retrospective record review. The span of time from initial treatment to recurrence will be assessed and summarized.

6 to 24 months post procedure
Aneurysm Retreatment
大体时间:6 to 24 months post procedure

The percentage of patients who required retreatment for a recurrence of aneurysm will be extracted and summarized based on a binary (Yes/No) determination following retrospective record review. The span of time from initial treatment to retreatment will be assessed and summarized.

6 to 24 months post procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年10月1日

初级完成 (估计的)

2027年7月1日

研究完成 (估计的)

2027年7月1日

研究注册日期

首次提交

2023年12月5日

首先提交符合 QC 标准的

2023年12月13日

首次发布 (实际的)

2023年12月18日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅